Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · Real-Time Price · USD
5.01
-0.32 (-6.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Genenta Science Employees
Genenta Science had 14 employees as of December 31, 2023.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$683,040
Market Cap
91.63M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Harvard Bioscience | 416 |
Veru Inc. | 189 |
Century Therapeutics | 165 |
OptimizeRx | 136 |
LENSAR | 130 |
HilleVax | 90 |
Immunic | 77 |
Zentek | 24 |
GNTA News
- 2 months ago - Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective” - GlobeNewsWire
- 2 months ago - Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer - GlobeNewsWire
- 8 months ago - Genenta Welcomes New Directors John L. Cantello, Lauren H. - GlobeNewsWire
- 11 months ago - Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors - GlobeNewsWire
- 1 year ago - Genenta to Present at Upcoming Scientific and Investor Conferences - GlobeNewsWire
- 1 year ago - Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments - GlobeNewsWire
- 1 year ago - The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma - GlobeNewsWire
- 1 year ago - Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing - GlobeNewsWire